Keine Story von Intravacc mehr verpassen.
  • 07.04.2021 – 09:53

    Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine

    Bilthoven, Netherlands (ots/PRNewswire) - - Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2 - Intranasal vaccine administration has significant advantages over injectables - OMV technology is a powerful vaccine platform for future pandemics Intravacc, a global leader in translational research and development of viral and bacterial ...